Aurobindo Pharma has informed that in furtherance to letter dated September 6, 2018, the Company enclosed a copy of the Press Release that is being issued by the Company on mutual termination of definitive agreement entered into for acquisition of commercial operations and three manufacturing facilities in USA from Sandoz Inc., USA, a Novartis Division by our wholly owned subsidiary, Aurobindo Pharma USA Inc., USA since approval from the US Federal Trade Commission for the transaction was not obtained within anticipated timelines.
The above information is a part of company’s filings submitted to BSE.
